R. Jeroen A. van Moorselaar
Amsterdam University Medical Centers, Amsterdam UMC Location VUmc, Prostate Cancer UK
Papers
13
Total Citations
450
H-Index
9
About
Dr. R. Jeroen A. van Moorselaar is a leading urological oncologist whose research centers on precision imaging and risk stratification in prostate cancer. His major contributions lie in validating the clinical utility of PSMA PET/CT—particularly with the tracer [18F]DCFPyL—for primary staging, lymph node assessment, and biochemical recurrence. His landmark SALT trial (106 citations) demonstrated the superiority of PSMA PET/CT over conventional imaging for pelvic lymph-node staging prior to extended dissection, directly impacting surgical decision-making. In the DeTeCT trial (47 citations), he explored the feasibility of PSMA-targeted biopsy by comparing PET findings to final histopathology. Dr. van Moorselaar has also pioneered the use of machine learning to analyze PSMA PET radiomics for non-invasive risk stratification (135 citations), and developed an online prediction model for post-prostatectomy incontinence using patient-reported outcomes (47 citations). His work consistently bridges advanced imaging, artificial intelligence, and patient-centered outcomes, with several studies exceeding 100 citations. By demonstrating that standardised uptake values on PSMA PET correlate with oncological outcomes, he has helped establish quantitative PET metrics as prognostic biomarkers, shaping contemporary prostate cancer management.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10